Unjoni Ewropea - Malti - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - prodotti oħra tas-sistema respiratorja - inomax, flimkien mal-'ventilazzjoni-appoġġ u l-oħra xierqa sustanzi attivi, huwa indikat għall-kura ta 'trabi tat-twelid ≥34-il-ġimgħa ġestazzjoni b'indeboliment respiratorju ipoksiku assoċjat ma' jew ekokardjografiku evidenza ta 'pressjoni għolja pulmonari, sabiex ittejjeb l-ammont ta' ossiġenu u tnaqqas il-ħtieġa għal ossiġenazzjoni ta 'membrana ekstrakorporali;bħala parti mill-kura ta' waqt u wara l-operazzjoni pressjoni pulmonari għolja fl-adulti u trabi tat-twelid, trabi u tfal żgħar, tfal u l-adoloxxenti, l-etajiet 0-17-il sena, flimkien mal-kirurġija tal-qalb, sabiex selettiv tnaqqis ta ' pressjoni arterjali pulmonari u jtejbu l-ventrikolu tal-lemin tal-funzjoni u l-ossiġenazzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

immedica pharma ab - emedastine difumarate - konġuntivite, allerġiku - oftalmoloġiċi - trattament sintomatiku ta 'konġuntivite allerġika staġjonali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - aġenti antineoplastiċi - klieb - trattament ta 'tumuri taċ-ċelluli taċ-ċelluli tal-klieb li ma jistgħux jerġgħu jiddaħħlu (grad 2 jew 3) b'riċettur ikkonfermat ta' c-kit tyrosine kinase.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosoppressanti - artrite rewmatojde (ra)kineret huwa indikat fl-adulti għall-kura tas-sinjali u s-sintomi ta 'ra flimkien ma' methotrexate, ma kellhomx respons adegwat għal methotrexate waħdu. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. perjodiċi deni syndromeskineret huwa indikat għall-kura ta 'dawn li ġejjin min-naħa perjodiċi deni sindromi fl-adulti, l-adoloxxenti, tfal u trabi ta' bejn 8 xhur u aktar bil-piż tal-ġisem ta ' 10 kg jew aktar:assoċjati mal-cryopyrin sindromi perjodiċi (limiti)kineret huwa indikat għat-trattament tal-limiti, inkluż:neonatal-onset multisystem marda infjammatorja (nomid) / kronika infantili newroloġiku, vaskulite, artikulari sindromu (cinca)muckle-bjar sindromu (mws)familjali kiesaħ min-naħa sindromu (fcas)familjali-mediterran deni (fmf)kineret huwa indikat għall-kura ta familjali-mediterran deni (fmf). kineret għandu jingħata flimkien ma ' colchicine, jekk xieraq. għadhom tal-diseasekineret huwa indikat fl-adulti, l-adoloxxenti, tfal u trabi ta 'bejn 8 xhur u aktar bil-piż tal-ġisem ta' 10 kg jew aktar għall-kura tal-xorta tal-marda, inklużi l-sistemika, artrite idjopatika Ġuvenili (sjia) u adulti bidu xorta tal-marda (aosd), bil-sistemiċi attivi karatteristiċi tal moderata għal attività għolja tal-marda, jew fil-pazjenti bl-issuktar ta'l-attività tal-marda wara l-kura ma ' mediċini mhux sterojdi kontra l-infjammazzjoni (nsaids) jew glukokortikojdi. kineret jista 'jingħata bħala monoterapija jew flimkien ma' mediċini anti-infjammatorji oħra u li jimmodifikaw il-marda mediċini anti-rewmatiċi (dmards).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab  - metformin hydrochloride, saxagliptin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze huwa indikat kif frozen tad-dieta u jeżerċitaw biex jitjieb il-kontroll ta ' glycaemic fil-pazjenti adulti età 18-il sena u aktar antiki ma tip-2 diabetes mellitus jirriżultax kkontrollata tagħhom bħala tollerat tad-doża ta ' metformin waħdu jew dawk diġà qed ittrattati bil-kombinazzjoni ta ' saxagliptin u metformin bħala pilloli separati. komboglyze huwa indikat ukoll f'kumbinazzjoni ma ' l-insulina (i. terapija ta ' kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti adulti minn 18-il sena u akbar b'dijabete tat-tip 2 mellitus meta l-insulina u metformin waħdu ma jipprovdux kontroll gliċemiku adegwat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi oħra, inibituri tal-proteina kinase - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - fasenra huwa indikat bħala żieda fit-trattament ta 'manteniment f'pazjenti adulti bi ħsara severa eżinofilika-ażma mhux ikkontrollati adegwatament, minkejja doża għolja ta' kortikosterojdi meħuda man-nifs biż-żieda fit-tul li jaġixxu β-agonisti.